QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
November 07, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
November 05, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
October 31, 2024 16:05 ET | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
October 22, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
September 09, 2024 08:30 ET | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
August 08, 2024 08:30 ET | Quoin Pharmaceuticals, Inc.
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites ...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
August 06, 2024 05:00 ET | Quoin Pharmaceuticals, Inc.
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024 16:10 ET | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
June 27, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia       Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
June 25, 2024 16:05 ET | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...